IBERCHEM-GROUP
The Iberchem Group announced today that it has completed the acquisition of Flavor Inn Corporation and Duomei, two flavour companies located in Malaysia and China respectively. These transactions come as the latest effort in the Group’s merger and acquisition strategy initiated last year with the purchase of South Africa’s Versachem. It brings to three the number of acquisitions carried out since the start of the Group’s financial relationship with European private equity firm Eurazeo in 2017.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200205005751/en/
Ramón Fernández, CEO of Iberchem Group states: “We are pleased to welcome Duomei and Flavor Inn within the Scentium family. This announcement represents another key step in the strategic expansion of Scentium (the flavour division of the Iberchem Group) in Asia, and also in the roll out of our M&A strategy at a Group level. We are confident that both companies will add value and expertise to our existing Flavour offer in China and South East Asia. Both Duomei and Flavor Inn share Scentium’s customer-centric culture and values. We are expecting a smooth integration of their activity into our organization in the upcoming year.”
Founded in 1996, Flavor Inn is a Malaysian flavour manufacturer offering tailored-made solutions to its wide portfolio of customers in the South East Asian region. Flavor Inn Corporation specialises in the development of both natural and artificial flavours for beverages, savoury, bakery and dairy products, and confectionery.
Nanchang Duomei Bio-Tech Co., Ltd (Duomei) is a flavour manufacturer based in Nanchang, capital of Jiangxi province in China. Established in 2008, the company quickly gained a reputation within the Chinese flavour industry thanks to its innovative manufacturing methods and dedicated customer service.
The terms of the transaction were not disclosed.
RECORD REVENUES FOR 2019 FISCAL YEAR
Iberchem Group also announced financial results for the full year ended December 31, 2019. Despite being amid the aftermath of the raw material crisis that shook the F&F industry in 2018, the Spanish group closed the year outperforming the initial objectives set out in its annual budget. The company reported net revenues of €174 million, representing a net increase of 19%. Throughout the year, the Group successfully registered strong top-line growth and maintained a positive business momentum. Augmenting its value in all of its geographic segments and categories, it increased its profitability throughout the year. The Group has demonstrated, once again, the strength of its fundamentals, representing a unique value proposition for its customers, suppliers, employees and shareholders.
The Iberchem Group increased again this year its CapEx program: last October, it completed the construction of its new R&D centre at its head office, adding over 3,000m2 of facilities dedicated exclusively to fragrance technologies. The Group also fully revamped the production plant of its flavour unit in Spain, expecting to increase the flavour offerings of the company by almost 40%.
About the Iberchem Group
Headquartered in Murcia, Spain, and selling in more than 120 countries, the Iberchem Group has a unique fast-to-customer business model, and benefits from 13 manufacturing facilities across the world and a workforce reaching over 800 employees. The Group operates under two different divisions: Iberchem for fragrances and Scentium for food flavours. Since its creation in 1985, the Group has enjoyed solid and interrupted double-digit growth making it one of the fastest growing company of the industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005751/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom